You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Inhibitor of neuronal voltage-gated Na+ channels. Exhibits anticonvulsant activity. Potentiates GABA-induced Cl- currents in HEK 293 cells expressing the GABAA receptor α1β2γ2 subtype combination. Can induce autophagy by inhibiting inositol synthesis. Also delays disease onset and prolongs survival in a mouse amyotrophic lateral sclerosis (ALS) model, as well as reducing motor neuron loss and altered muscle morphology.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 236.27. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.23 mL||21.16 mL||42.32 mL|
|5 mM||0.85 mL||4.23 mL||8.46 mL|
|10 mM||0.42 mL||2.12 mL||4.23 mL|
|50 mM||0.08 mL||0.42 mL||0.85 mL|
References are publications that support the biological activity of the product.
Granger et al (1995) Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamaz. and phen. Mol.Pharmacol. 47 1189 PMID: 7603459
Afanas'ev et al (1999) Lamotrigine and carbamaz. affect differently the release of D-[3H] aspartate from mouse cerebral cortex slices: involvement of NO. Neurochem.Res. 24 1153 PMID: 10485587
Lipkind and Fozzard (2010) Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol.Pharmacol. 78 631 PMID: 20643904
Sarkar et al (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16 46 PMID: 18636076
Galluzzi et al (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat.Rev.Drug.Discov. 16 487 PMID: 28529316
Zhang et al (2018) Repurposing carbamaz. for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model. CNS Neurosci.Ther. 24 1163 PMID: 29656576
If you know of a relevant reference for Carbamazepine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Carbamazepine, Carbamazepine supplier, sodium, Na+, channels, GABAA, ligands, inhibits, inhibitors, anticonvulsants, CBZ, Voltage-gated, Sodium, Channels, Autophagy, 4098, Tocris Bioscience
Citations for Carbamazepine
Citations are publications that use Tocris products.
Currently there are no citations for Carbamazepine. Do you know of a great paper that uses Carbamazepine from Tocris? Please let us know.
Reviews for Carbamazepine
Average Rating: 5 (Based on 1 Review.)
Have you used Carbamazepine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Carbamazepine's effect on serotonin systems observed and an attempt to explain how it exert it's antiseizure effects was made.
There is evidence that it is a serotonin releasing agent and possibly even a serotonin reuptake inhibitor
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.